

Resource Summary Report

Generated by [RRID](#) on Jul 29, 2026

Brilliant Violet 650(TM) anti-mouse CD19

RRID:AB_11204087

Type: Antibody

Proper Citation

BioLegend Cat# 115541, RRID:AB_11204087

Antibody Information

URL: http://antibodyregistry.org/AB_11204087

Proper Citation: BioLegend Cat# 115541, RRID:AB_11204087

Target Antigen: CD19

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 650(TM) anti-mouse CD19

Description: This monoclonal targets CD19

Target Organism: mouse

Clone ID: Clone 6D5

Antibody ID: AB_11204087

Vendor: BioLegend

Catalog Number: 115541

Record Creation Time: 20250820T022311+0000

Record Last Update: 20250820T132712+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 650(TM) anti-mouse CD19.

No alerts have been found for Brilliant Violet 650(TM) anti-mouse CD19.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 42 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Farré Díaz C, et al. (2026) FOXO1 re-expression with a dual-recombinase allele rescues class switching in germinal center B cells. *The Journal of experimental medicine*, 223(3).

Xu Y, et al. (2026) A dysregulated hepcidin-iron axis impairs antiviral immunity and induces lethal liver pathology in neonates. *Immunity*, 59(1), 79.

Song H, et al. (2025) Targeting tumor monocyte-intrinsic PD-L1 by rewiring STING signaling and enhancing STING agonist therapy. *Cancer cell*, 43(3), 503.

Butler TD, et al. (2025) Colonic inflammation modulates the intestinal circadian landscape. *iScience*, 28(8), 113183.

Lanzar ZR, et al. (2025) IL-27 promotes Treg cell expression of CD122 and fitness at homeostasis. *Proceedings of the National Academy of Sciences of the United States of America*, 122(50), e2519141122.

Mears KS, et al. (2025) Therapeutic activation of IL-22-producing innate lymphoid cells enhances host defenses to *Clostridioides difficile* infection. *Cell reports*, 44(4), 115438.

Ahn JJ, et al. (2025) Coupling IL-2 with IL-10 to mitigate toxicity and enhance antitumor immunity. *Cell reports. Medicine*, 6(8), 102257.

Lanzar ZR, et al. (2025) De-coupling immune parameters and toxicity associated with IL-12 agonism. *Cell reports*, 44(6), 115840.

Chen J, et al. (2025) Identification and validation of intratumoral microbiome associated with sensitization to immune checkpoint inhibitors. *Cell reports. Medicine*, 6(9), 102306.

Chandra V, et al. (2024) Gut epithelial Interleukin-17 receptor A signaling can modulate distant tumors growth through microbial regulation. *Cancer cell*, 42(1), 85.

Collins A, et al. (2024) Maternal inflammation regulates fetal emergency myelopoiesis. *Cell*, 187(6), 1402.

Denny JE, et al. (2024) Monoclonal antibody-mediated neutralization of *Clostridioides difficile* toxin does not diminish induction of the protective innate immune response to infection. *Anaerobe*, 88, 102859.

Xu L, et al. (2024) Expression of a mutant CD47 protects against phagocytosis without inducing cell death or inhibiting angiogenesis. *Cell reports. Medicine*, 5(3), 101450.

Wang B, et al. (2024) Intermittent clearance of p21-highly-expressing cells extends lifespan and confers sustained benefits to health and physical function. *Cell metabolism*, 36(8), 1795.

Zhang J, et al. (2024) Endothelial metabolic control of insulin sensitivity through resident macrophages. *Cell metabolism*, 36(11), 2383.

Kazer SW, et al. (2024) Primary nasal influenza infection rewires tissue-scale memory response dynamics. *Immunity*, 57(8), 1955.

Mahadevan KK, et al. (2023) Elimination of oncogenic KRAS in genetic mouse models eradicates pancreatic cancer by inducing FAS-dependent apoptosis by CD8+ T cells. *Developmental cell*, 58(17), 1562.

Chaudagar K, et al. (2023) Suppression of Tumor Cell Lactate-generating Signaling Pathways Eradicates Murine PTEN/p53-deficient Aggressive-variant Prostate Cancer via Macrophage Phagocytosis. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 29(23), 4930.

Prokhnevskaya N, et al. (2023) CD8+ T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor. *Immunity*, 56(1), 107.

Eschweiler S, et al. (2023) JAML immunotherapy targets recently activated tumor-infiltrating CD8+ T cells. *Cell reports*, 42(2), 112040.